Monitor the CLBP Phase 3 readout in H2 CY2027 and the adult SR-aGvHD interim analysis in Q4 CY2027 as key catalysts. The LVAD BLA filing timeline and potential cardiopulmonary partnership are also important milestones. Ryoncil revenue trajectory in FY2027 will signal commercial execution.
Drugs in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $13.65entry
- T+1 · 5d ago −4.03%α −3.68% · $13.10
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast held its 2026 Annual General Meeting, reporting FY2026 Ryoncil net revenue of $115M, completing enrollment in the pivotal Phase 3 CLBP trial, and announcing FDA alignment for a BLA filing for rexlemestrocel-L in LVAD patients. The company appointed an interim COO to prepare for commercial scale-up, while two directors retired and one new director was elected. The filing is a routine AGM update with no new financial data beyond previously reported figures.
Key Facts
- FY2026 Ryoncil net revenue of $115M, gross profit of $110M excluding amortization
- Phase 3 CLBP trial fully enrolled with 350 patients; readout expected H2 CY2027
- FDA alignment obtained for BLA filing of rexlemestrocel-L in LVAD patients with GI bleeding
- Adult SR-aGvHD registrational trial commenced, targeting 40 US sites; interim analysis expected Q4 CY2027
- Dr. Gregory George appointed interim COO; Dr. Eric Rose steps away from Board to focus as CMO
- William Burns and Philip Krause retired from the Board; Jon Voigtman elected as director
- All AGM resolutions carried, including adoption of remuneration report and equity incentive plans
Financial Impact
FY2026 Ryoncil net revenue $115M, gross profit $110M; company remains unprofitable with accumulated losses of $1.07B per prior 20-F
Risk Factors
- CLBP Phase 3 trial may fail to meet primary endpoint
- Adult SR-aGvHD trial enrollment or results may disappoint
- Company remains unprofitable with significant accumulated losses
- Pipeline candidates face clinical and regulatory risks
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000097 |
| Exhibit: exhibit9932026agmappendi.htm | 0001345099-26-000097 |
| Exhibit: exhibit9942026agmappendi.htm | 0001345099-26-000097 |
| Exhibit: exhibit9912026agmappendi.htm | 0001345099-26-000097 |
| Exhibit: exhibit9962026agmappendi.htm | 0001345099-26-000097 |
| Exhibit: exhibit9952026agmappendi.htm | 0001345099-26-000097 |
| Document: form6-kxpressreleasecoverf.htm | 0001345099-26-000097 |
| Document: 0001345099-26-000097-index-headers.html | 0001345099-26-000097 |
| Document: 0001345099-26-000097-index.html | 0001345099-26-000097 |
| Document: 0001345099-26-000097.txt | 0001345099-26-000097 |
| Earnings Context (Synthetic; results releases only) | 0001345099-26-000097 |
Track record
25 reports on MESO
7 of 15 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Viewing Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers